Theratechnologies Inc T.TH

RE:RE:RE:RE:Most promising…

[palinc2000]

Anything that gets the SP to at least 5$ would allow them to start drawing under the ATM  .....the amount that they draw would be quite revealing as to their expectations of the path of the SP

SPCEO1 wrote: If the phase 1b info they already have points to the high liklihood of a phase 2 trial just ahead, there will be a need for cash to help fund that. That could come from partnerships or it could come from investors,or both. It seems to me the evidence we have is pointing towards a share offering. If so, TH is probably going to release any interesting info in a way to optimize the eventual share offering. So, that means they will hold onto whatever info they are allowed to hold onto until such time as it makes sense to release it to attract investors to its stock sale.

While I am not expecting any news next week, it is possible they announce something prior to the Cantor conference in order to attract attention to what TH is doing in cancer just like they published the CSC paper just before heading out to speak with investors with Research Capital last week. 

As already noted, good phase 1b results will result in at least one phase 2 trial and TH will want to raise money for those trial costs. The fact that Canaccord gave TH aseemingly undeserved very good slot at its conference in August to  TH, that the previously apathetic Canaccord analyst also updated his model for TH and raised his price target on no news, that Research Capital took TH out on a non-deal roadshow in Montreal and Toronto and that now Cantor has given TH a spot on one of their high profile panels at their upcoming cancer conference all suggests preparations are being laid for a share offering and the brokers are all angling to be in on this lucrative piece of business for them. That "dance" between TH and the brokers as both prepare for an eventual offering is the best evidence we currently have that something good is going on in the phase 1b since it would not be happening if there was nothing to TH-1902.

qwerty22 wrote:

Yep, I specifically went looking for new patents last week and found nothing, you're clearly better at this than me.

I guess this explains the timing of the CSC paper to some extent. It's possible there are more revelations about the action of the drugs waiting for IP. At the bottom it also indicates that Chinese IP of the original PDC patent was recently accepted. They're almost wilfully choosing to NOT talk about these little but important successes.

(The IP I'm waiting for is something about exosome, just my pet fantasy. See if you can find that Scarlett)

 

palinc2000 wrote:

 

Great find as always Scarlett!
 

 

scarlet1967 wrote:

 

They filed the WO patent in February and it was published this month. Cancer stem cells as per latest research are present in various types of cancers including:

Breast, Colon, Ovary, Pancreas, Prostate, Melanoma, Multiple Myeloma, Non-melanoma skin cancer…

Although this research is early in the process it seems if and when they can duplicate the results in humans it can add significant value to the potential treatment against metastatic cancers.

From the patent application:

 

 

 

“Nearly all current cancer treatments focus on de-bulking tumors without targeting the most dangerous cells in the tumor: cancer stem cells (CSCs). CSCs are responsible for the spread of cancer cells throughout the body, the growth of tumors, cancer’s resistance to chemotherapy, and the recurrence of tumors after treatment or surgical removal, notably through their ability to arrest in the GO phase, giving rise to new tumors. Because current treatments do not target the CSC population, they frequently lead to the rise of resistant tumors and continued cancer spread. Therefore, CSCs could be considered the most promising targets for cancer treatment. There is thus a need for the development of strategies for the treatment of cancer, and more particularly cancers associated with CSCs, for example to overcome tumor resistance to cancer therapy, and prevent/treat cancer relapse and improve survival in cancer patients.”

 

https://patents.google.com/patent/WO2022178634A1/en